NephMadness 2019

NephMadness is a nephrology-focused online interactive medical education activity. While it has been around for 7 years, this is only the second year that CME/CE credit will be offered for players, and first for MOC! Social media, interactivity, and gamification will teach the latest advances and the most important breakthroughs in nephrology.

There are 8 general themes (called “regions”) broken down into 4 specific nephrology concepts (called “teams”). Teams compete against each other in a single elimination contest. We have selected content experts from each region to make sure the information we present is accurate, unbiased, and interesting. For details, read the explanatory post here.

Target Audience

  • Physicians
Method of Participation:
  • Read the 8 “region” summaries that cover the 32 nephrology concept teams at the AJKD blog here. Earn up to 1.0 credit per region.
  • Complete a bracket with your predictions of what concepts are the most important or most impactful here
  • Participate in social media (using #NephMadness on Twitter, Instagram, Facebook, blog) discussions about these concepts, sharing your opinions of what is the most important or impactful to you in nephrology.
  • Login or create an account to this site
  • Complete the post-test (for only the regions you participated in) 
  • Submit your evaluation 
  • Claim credit (1 region = 1 credit/MOC)
  • Download your certificate

Learning Objectives

After this activity learners will be better able to:

  • Discuss the current guidelines and updates for the treatment of hypertension
  • Review the updated diagnosis and treatment algorithms for primary hyperaldosteronism
  • Review technological advances in volume assessment and compare them to traditional methods 
  • Identify the benefits of achieving dry weight in patients on hemodialysis and the adverse patient reported outcomes that may be associated
  • Define the role of complement in the pathophysiology of C3 glomerulopathy and how it guides treatment
  • Identify the role of terminal complement inhibitors that are currently available, in addition to novel inhibitors that are currently being tested for more specific targets in the complement pathway
  • Identify the spectrum of kidney injury that can occur as a result of the physiology associated with extreme exercise and toxicities that can occur with supplements
  • Identify the role, risks, and benefits of exercise in patients with end-stage kidney disease on dialysis, and also in patients who have receive kidney transplants 
  • Recognize the role of NSAIDs, opiates, and other medications for pain management in patients with kidney disease
  • Review the use of angiotensin-converting-enzyme inhibitors (ACE-I) and PRN’s in hospitalized patients
  • Identify the pros and cons of various isotonic crystalloid solutions for the use of volume resuscitation in hospitalized patients
  • Recognize the role of bile-acids and bilirubin in the role of nephrotoxicity in the setting of patients with advanced liver disease
  • Identify the medical treatment options for hepatorenal syndrome.Identify the role of plasma exchange in the treatment of antineutrophil cytoplasmic antibodies (ANCA) vasculitis as well as multiple myeloma and cast nephropathy
  • Identify the role of plasma exchange in both the pre and post-transplant period for both optimization of graft function and prevention of recurrent disease
Additional information
AttachmentSize
NephMadness Bracket645.59 KB
Course summary
Available credit: 
  • 8.00 AMA PRA Category 1 Credit™
  • 8.00 Attendance
  • 8.00 ABIM MOC
Course opens: 
03/15/2019
Course expires: 
06/15/2019
Cost:
$0.00
Rating: 
0
Faculty Disclosures:

Samantha Gelfand, MD
University of Pennsylvania
Philadelphia, PA
Disclosure: Has no financial relationships with commercial interest(s).

Matthew Graham-Brown, MD
University of Leicester
Leicester, England
Disclosure: Has no financial relationships with commercial interest(s).

Swapnil Hiremath, MD
University of Ottawa
Ottawa, CAN
Disclosure: Has no financial relationships with commercial interest(s).

Anuja Java, MD
Washington University in St. Louis
St. Louis, MO
Disclosure: Has no financial relationships with commercial interest(s).

Pascale Khairallah, MD
Columbia University
New York, NY
Disclosure: Has no financial relationships with commercial interest(s).

Devika Nair, MD
Vanderbilt University Medical Center
Nashville, TN
Disclosure: Has no financial relationships with commercial interest(s).

Paul Phelan, MB, BCh BAO, MD, FRCP 
NHS Lothian  
Edinburgh, United Kingdom  
Disclosure: Has no financial relationships with commercial interest(s).  

William Whittier , MD
Rush University
Chicago, IL
Disclosure: Has no financial relationships with commercial interest(s).

Planning Committee Disclosures:

Jeffrey Berns, MD
University of Pennsylvania
Philadelphia, PA
Disclosure: Consultant: Bayer

Anna Burgner, MD, MEHP
Vanderbilt Medical Center
Nashville, TN 
Disclosure: Research Support: FibroGen, Bayer, inRegen, AstraZeneca

Stanley Goldfarb, MD
University of Pennsylvania
Philadelphia, PA
Disclosure: Consultant: Fresenius; Advisory Board: Ligand Pharma  

David Juurlink, MD, PhD
Sunnybrook Health Sciences Center
Toronto, CAN
Disclosure: Has no financial relationships with commercial interest(s).

Andre Kaplan, MD
University of Connecticut Health Center
Farmington, CT
Disclosure: Consultant: VitalTherapeutics

Maryam Khosravi, MD, PhD
University College London
London, United Kingdom
Disclosure: Has no financial relationships with commercial interest(s).

Danielle Nathan, MA
Senior Director, Professional Education
National Kidney Foundation
New York, NY
Disclosure: Has no financial relationships with commercial interest(s).

Carla Nester, MD
University of Iowa 
Iowa City, IA
Disclosure: Research support: Alexion, Achillion, Retrophin, Chemocentryx 

Chirag Parikh, MBBS, PhD
Johns Hopkins University 
Baltimore, MD
Disclosure: Has no financial relationships with commercial interest(s).

Tariq Shafi, MBBS, MHS
Johns Hopkins University 
Baltimore, MD
Disclosure: Has no financial relationships with commercial interest(s).

Matthew A. Sparks, MD
Duke University Medical Center/Durham VA Medical Center
Durham, NC
Disclosure: Has no financial relationships with commercial interest(s).

Susan Steigerwalt, MD
University of Michigan
Ann Arbor, MI
Disclosure: Consulting fee: Medtronic 

Joel M. Topf, MD
St. Clair Specialty Physicians
Roseville, MI 
Disclosure: Consulting fee: DaVita; Travel: Takeda Oncology; Dividend: DaVita

Juan Carlos Velez, MD
Ochsner Clinic Foundation 
New Orleans, LA 
Disclosure: Honoraria: Mallinckrodt, Otsuka  

Dan Weiner, MD
Tufts University 
Boston, MA 
Disclosure: Consulting fee: Akebia, Janssen; Salary support: Dialysis Clinic Inc. 

Charlie Wray, DO, MS 
University of California San Francisco 
San Francisco, CA
Disclosure: Has no financial relationships with commercial interest(s).

Timothy Yau, MD
Washington University School of Medicine 
St. Louis, MO 
Disclosure: Has no financial relationships with commercial interest(s).

Declaration of Disclosure:

It is the policy of the National Kidney Foundation (NKF) to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. Any individual who has control over CME/CE content is required to disclose to learners prior to the activity any relevant financial relationship(s) they may have with commercial interests supporting this activity or whose products or devices are discussed in this activity.  

If, on the basis of information disclosed, a perceived conflict exists, resolution will be achieved based on NKF's Disclosure and Conflict of Interest Policy.

Unlabeled/Investigational Use:

During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

In support of improving patient care, the National Kidney Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician

The National Kidney Foundation designates this enduring activity for a maximum of 8.0 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Available Credit

  • 8.00 AMA PRA Category 1 Credit™
  • 8.00 Attendance
  • 8.00 ABIM MOC

Accreditation Period

Course opens: 
03/15/2019
Course expires: 
06/15/2019

Price

Cost:
$0.00
Please login or register for a PERC account to take this course.
Disclaimer:

The faculty and National Kidney Foundation (NKF) do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindications, and warnings.

Information contained in this NKF educational resource is based upon current data available at the time of publication. Information is intended to help clinicians become aware of new scientific findings and developments.  This NKF educational resource is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management.

Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional making use of information in this NKF educational resource is responsible for interpreting the data as it pertains to clinical decision making in each individual patient.

Required Hardware/software

System Requirements 

For hardware/software and internet connectivity requirements for participation in this CME/CE activity, visit kidney.org/cme and click on System Requirements for Participation.

Contact Information

For any questions concerning this activity, please send an email to CMEinfo@kidney.org or call NKF at 1-800-622-9010.
To view NKF privacy and confidentiality policy as it relates to CME/CE activity, please visit http://www.kidney.org/
For additional professional education resources, contact NKF at 1-800-622-9010 or visit https://www.kidney.org/professionals